Table 2.

Reported results of FMT for corticosteroid-refractory GVHD.

Reference	Data Source	Number of Patients (n)	Outcome	Adverse Events
Kakihana et al. [58]	Single center prospective study	4 (received a total of 7 FMT by nasogastric administration)	3 CR and 1 PR	1 case of lower gastrointestinal bleed and hypoxemia, may not be related to FMT
Spindelboeck et al. [59]	Retrospective case series	3 (received a total of 9 FMT by colonoscopy)	2 CR and 1 PR	None reported
Qi et al. [60]	Single center prospective study	8 (received a total of 12 FMT by nasogastric administration)	5 CR and 1 PR	None reported
Shouval et al. [61]	Single center prospective study	7 (received a total of 15 FMT by capsule administration)	2 CR	2 episodes of bacteremia, deemed unrelated to FMT
van Lier et al. [62]	Single center prospective study	15 (received a total of 15 FMT by nasoduodenal tube administration)	10 CR	None reported
Zhao et al. [63]	Single center open-label Phase I/II study	41 (23 assigned to FMT and 18 to control. FMT administered by nasojejunal or gastric tube)	Overall response rate of 82.6% (52.2% CR and 30.4% PR) in the FMT group and 39% (all PR) in the control group on Day 14 after FMT, and an overall response rate of 69.5% (56.5% CR and 13% PR) in the FMT group and 50% (16% CR and 34% PR) in the control group on Day 21 after FMT	No difference in the adverse events between the FMT group and the control group.
Goeser et al. [64]	Two-center retrospective study	11 (9 by capsule and 2 by nasojejunal tube administration)	Attenuation of stool volume and frequency was observed in all 11 patients	Abdominal pain occurred in 3 patients and vomiting in 1 patient
Mao et al. [65]	Case report	1 (received two cycles of FMT administered by capsules)	CR	None reported